Cargando…
Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
The results of the recent Step Study highlight a need to clarify the effects of pre-existing natural immunity to a vaccine vector on vaccine-induced T-cell responses. To investigate this interaction, we examined the relationship between pre-existing Ad5 immunity and T-cell cytokine response profiles...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076372/ https://www.ncbi.nlm.nih.gov/pubmed/21533229 http://dx.doi.org/10.1371/journal.pone.0018526 |
_version_ | 1782201829937905664 |
---|---|
author | Pine, Samuel O. Kublin, James G. Hammer, Scott M. Borgerding, Joleen Huang, Yunda Casimiro, Danilo R. McElrath, M. Juliana |
author_facet | Pine, Samuel O. Kublin, James G. Hammer, Scott M. Borgerding, Joleen Huang, Yunda Casimiro, Danilo R. McElrath, M. Juliana |
author_sort | Pine, Samuel O. |
collection | PubMed |
description | The results of the recent Step Study highlight a need to clarify the effects of pre-existing natural immunity to a vaccine vector on vaccine-induced T-cell responses. To investigate this interaction, we examined the relationship between pre-existing Ad5 immunity and T-cell cytokine response profiles in healthy, HIV-uninfected recipients of MRKAd5 HIV-1 gag vaccine (HVTN 050, ClinicalTrials.gov #NCT00849732). Participants were grouped by baseline Ad5 neutralizing antibody titer as either Ad5-seronegative (titer ≤18; n = 36) or Ad5-seropositive (titer >200; n = 34). Samples from vaccine recipients were analyzed for immune responses to either HIV-1 Gag peptide pools or Ad5 empty vector using an ex vivo assay that measures thirty cytokines in the absence of long-term culture. The overall profiles of cytokine responses to Gag and Ad5 had similar combinations of induced Th1- and Th2-type cytokines, including IFN-γ, IL-2, TNF-α, IP-10, IL-13, and IL-10, although the Ad5-specific responses were uniformly higher than the Gag-specific responses (p<0.0001 for 9 out of 11 significantly expressed analytes). At the peak response time point, PBMC from Ad5-seronegative vaccinees secreted significantly more IP-10 in response to Gag (p = 0.008), and significantly more IP-10 (p = 0.0009), IL-2 (p = 0.006) and IL-10 (p = 0.05) in response to Ad5 empty vector than PBMC from Ad5-seropositive vaccinees. Additionally, similar responses to the Ad5 vector prior to vaccination were observed in almost all subjects, regardless of Ad5 neutralizing antibody status, and the levels of secreted IFN-γ, IL-10, IL-1Ra and GM-CSF were blunted following vaccination. The cytokine response profile of Gag-specific T cells mirrored the Ad5-specific response present in all subjects before vaccination, and included a number of Th1- and Th2-associated cytokines not routinely assessed in current vaccine trials, such as IP-10, IL-10, IL-13, and GM-CSF. Together, these results suggest that vector-specific humoral responses may reduce vaccine-induced T-cell responses by previously undetected mechanisms. |
format | Text |
id | pubmed-3076372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30763722011-04-29 Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans Pine, Samuel O. Kublin, James G. Hammer, Scott M. Borgerding, Joleen Huang, Yunda Casimiro, Danilo R. McElrath, M. Juliana PLoS One Research Article The results of the recent Step Study highlight a need to clarify the effects of pre-existing natural immunity to a vaccine vector on vaccine-induced T-cell responses. To investigate this interaction, we examined the relationship between pre-existing Ad5 immunity and T-cell cytokine response profiles in healthy, HIV-uninfected recipients of MRKAd5 HIV-1 gag vaccine (HVTN 050, ClinicalTrials.gov #NCT00849732). Participants were grouped by baseline Ad5 neutralizing antibody titer as either Ad5-seronegative (titer ≤18; n = 36) or Ad5-seropositive (titer >200; n = 34). Samples from vaccine recipients were analyzed for immune responses to either HIV-1 Gag peptide pools or Ad5 empty vector using an ex vivo assay that measures thirty cytokines in the absence of long-term culture. The overall profiles of cytokine responses to Gag and Ad5 had similar combinations of induced Th1- and Th2-type cytokines, including IFN-γ, IL-2, TNF-α, IP-10, IL-13, and IL-10, although the Ad5-specific responses were uniformly higher than the Gag-specific responses (p<0.0001 for 9 out of 11 significantly expressed analytes). At the peak response time point, PBMC from Ad5-seronegative vaccinees secreted significantly more IP-10 in response to Gag (p = 0.008), and significantly more IP-10 (p = 0.0009), IL-2 (p = 0.006) and IL-10 (p = 0.05) in response to Ad5 empty vector than PBMC from Ad5-seropositive vaccinees. Additionally, similar responses to the Ad5 vector prior to vaccination were observed in almost all subjects, regardless of Ad5 neutralizing antibody status, and the levels of secreted IFN-γ, IL-10, IL-1Ra and GM-CSF were blunted following vaccination. The cytokine response profile of Gag-specific T cells mirrored the Ad5-specific response present in all subjects before vaccination, and included a number of Th1- and Th2-associated cytokines not routinely assessed in current vaccine trials, such as IP-10, IL-10, IL-13, and GM-CSF. Together, these results suggest that vector-specific humoral responses may reduce vaccine-induced T-cell responses by previously undetected mechanisms. Public Library of Science 2011-04-13 /pmc/articles/PMC3076372/ /pubmed/21533229 http://dx.doi.org/10.1371/journal.pone.0018526 Text en Pine et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Pine, Samuel O. Kublin, James G. Hammer, Scott M. Borgerding, Joleen Huang, Yunda Casimiro, Danilo R. McElrath, M. Juliana Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans |
title | Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans |
title_full | Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans |
title_fullStr | Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans |
title_full_unstemmed | Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans |
title_short | Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans |
title_sort | pre-existing adenovirus immunity modifies a complex mixed th1 and th2 cytokine response to an ad5/hiv-1 vaccine candidate in humans |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076372/ https://www.ncbi.nlm.nih.gov/pubmed/21533229 http://dx.doi.org/10.1371/journal.pone.0018526 |
work_keys_str_mv | AT pinesamuelo preexistingadenovirusimmunitymodifiesacomplexmixedth1andth2cytokineresponsetoanad5hiv1vaccinecandidateinhumans AT kublinjamesg preexistingadenovirusimmunitymodifiesacomplexmixedth1andth2cytokineresponsetoanad5hiv1vaccinecandidateinhumans AT hammerscottm preexistingadenovirusimmunitymodifiesacomplexmixedth1andth2cytokineresponsetoanad5hiv1vaccinecandidateinhumans AT borgerdingjoleen preexistingadenovirusimmunitymodifiesacomplexmixedth1andth2cytokineresponsetoanad5hiv1vaccinecandidateinhumans AT huangyunda preexistingadenovirusimmunitymodifiesacomplexmixedth1andth2cytokineresponsetoanad5hiv1vaccinecandidateinhumans AT casimirodanilor preexistingadenovirusimmunitymodifiesacomplexmixedth1andth2cytokineresponsetoanad5hiv1vaccinecandidateinhumans AT mcelrathmjuliana preexistingadenovirusimmunitymodifiesacomplexmixedth1andth2cytokineresponsetoanad5hiv1vaccinecandidateinhumans |